Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD

Market Cap$120.22B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Gilead Sciences, Inc.Gilead Sciences, Inc.955.73.17%-4.4-

Earnings Call Q3 2024

November 6, 2024 - AI Summary

**Strong Financial Performance**: Gilead reported total product sales of $7.5 billion in Q3 2024, reflecting a 7% year-over-year increase. The base business, excluding Veklury, grew by 7% to $6.8 billion, driven by robust sales across HIV, Oncology, and Liver Disease.
**Updated Guidance**: The company has raised its full-year 2024 revenue guidance to $27.8 billion to $28.1 billion, an increase of $650 million at the midpoint, primarily due to better-than-expected performance in HIV and Veklury, which is now expected to generate approximately $1.8 billion in sales.
**HIV Treatment and Prevention Growth**: Sales in the HIV segment were strong, reaching $5.1 billion in Q3, up 9% year-over-year. With an anticipated regulatory filing for lenacapavir for PrEP by the end of 2024, Gilead expects to capitalize on the growing demand for HIV prevention treatments.

Exclusive for Stockcircle Pro members

Sign upSign Up
$87.18

Target Price by Analysts

10.1% downsideGilead Sciences Target Price DetailsTarget Price
$265.78

Current Fair Value

173.9% upside

Undervalued by 173.9% based on the discounted cash flow analysis.

Share Statistics

Market cap$120.22 Billion
Enterprise Value$120.22 Billion
Dividend Yield$3.08 (3.16884999741107%)
Earnings per Share$4.54
Beta0.2
Outstanding Shares1,247,000,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio955.69
PEG-2247.46
Price to Sales4.41
Price to Book Ratio2.85
Enterprise Value to Revenue4.25
Enterprise Value to EBIT13.99
Enterprise Value to Net Income954
Total Debt to Enterprise0
Debt to Equity-

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Gilead Sciences, Inc.

CEO: Daniel O'Day